Why Most People Can't Access Modern Depression Treatments

TL;DR

• Modern "interventional" depression treatments work — TMS, ketamine, esketamine (Spravato), VNS, ECT — but most patients who could benefit can't access them.
• The bottleneck is no longer evidence. A panel of clinicians and operators at APA 2026 made this explicit: the question has shifted from "does this work?" to "how do we get it to everyone who needs it?"
• Four main barriers: workforce (not enough trained providers), reimbursement (insurance often doesn't cover), delivery model (in-clinic infusion centers are inherently limited), and patient awareness (most patients don't know these options exist).
• Telehealth-supervised at-home ketamine therapy is one of the answers to delivery-model scaling — it removes geographic and time barriers that in-clinic infusion centers can't.
• Workforce expansion is the slowest piece. Training enough psychiatrists, nurse practitioners, and integration therapists takes years.

This is part of a series of patient-facing posts translating what was discussed at the American Psychiatric Association's 2026 Annual Meeting.

The session

On Sunday afternoon at APA 2026, four operators in the interventional psychiatry space sat on a panel called "From Specialty to Standard: How Do We Scale Interventional Psychiatry?" The panelists weren't researchers presenting data. They were people running clinics, building companies, and treating patients today:

• Andrew Gerber, MD — President and Medical Director (treatment-resistant depression specialty practice)
• William Sauve, MD — Chief Medical Officer (TMS and interventional psychiatry network)
• Owen Muir, MD — Independent psychiatrist and a public voice on these topics
• Mimi Winsberg, MD — Co-founder of Brightside Health, formerly Ginger.io

The framing — explicitly: the evidence is here, but the patients can't reach it. I think this is the single most important conversation happening in psychiatry right now, and the fact that it took place on the main APA stage matters.

What's actually working today

Before getting to the barriers, the panel acknowledged what does work:

• TMS (transcranial magnetic stimulation) is FDA-approved for depression, OCD, and several other conditions. Around 1,500 dedicated TMS clinics now operate in the U.S. Most major insurance plans cover it for treatment-resistant depression.
• Spravato (esketamine) is FDA-approved for treatment-resistant depression. Coverage has expanded; in-clinic administration requirement remains a workflow burden.
• IV ketamine is widely used off-label. Cash-pay infusion clinics are common in major metros.
• At-home oral and sublingual ketamine through telehealth-supervised programs (like Isha Health) — accessible in most states, prescription-based.
• ECT (electroconvulsive therapy) — still the most effective treatment for severe, life-threatening depression, available at most major medical centers.

Each of these has solid evidence. Each is reaching far fewer patients than it could.

The four barriers, in plain English

Barrier 1: Not enough trained providers

Delivering interventional treatments requires specific training that most psychiatrists didn't get in residency. TMS requires technician training and physician oversight. Ketamine therapy requires understanding dosing, monitoring, and integration. Spravato requires REMS certification.

The result: even where treatments are technically available, the workforce capacity is small. Most psychiatric residencies still don't include hands-on training in interventional modalities. Filling that gap is a multi-year process — the people training today will be at full capacity in 2-5 years.

Barrier 2: Reimbursement is patchy and slow

Three things make insurance reimbursement uneven:

• FDA-approved vs. off-label: Spravato is approved and covered for TRD. Racemic ketamine (the standard form) is off-label and rarely covered.
• In-clinic vs. at-home: insurance generally prefers in-clinic procedures even when at-home protocols are cheaper and equally effective. This is a structural mismatch.
• Diagnosis requirements: getting coverage for Spravato requires a formal treatment-resistant depression diagnosis with documented prior medication failures. Many patients who would benefit don't have this paper trail.

For most patients receiving interventional treatments today, the practical answer is HSA/FSA accounts, cash pay, or partial coverage with significant out-of-pocket cost. This filters access by income.

Barrier 3: Delivery model — in-clinic vs. at-home

This is where the conversation got most pointed.

In-clinic infusion centers have a fundamental limit: they require patients to physically travel to a specific location for 1-2 hours per session, multiple times per week initially. This makes the math hard:

• A typical IV ketamine clinic serves maybe 5-15 patients per day, per chair
• Most patients live more than 30 minutes from a clinic
• Time off work, childcare, transportation, and stigma all reduce who can actually attend

Telehealth-supervised at-home protocols solve most of this. Patients have video visits with a physician, receive a prescription that ships to their home, complete sessions in their own space with telehealth support, and return for follow-up via video. The geographic and time constraints largely go away.

This is what Isha Health does. We're not the only one — Mindbloom, Innerwell, and several others operate similar telehealth-supervised programs. The conversation at the panel was explicit: at-home delivery is one of the answers to scale, not a workaround. It just doesn't fit the existing reimbursement infrastructure built around in-clinic procedures.

Barrier 4: Most patients don't know these options exist

If you're reading this post, you're already ahead of most patients. The typical patient with treatment-resistant depression knows about SSRIs and SNRIs. They've heard of therapy. They may have heard of "ketamine clinics" but assume they're either fringe or only for the very wealthy.

They generally have not heard:

• That ketamine therapy is now Step 3-4 of the standard depression treatment ladder — not the last resort
• That at-home protocols are an option
• That Spravato is FDA-approved and covered by insurance for TRD
• That TMS is FDA-approved and widely available for moderate-to-severe depression

This is an information problem as much as a delivery problem. The treatments that exist are not reaching the people who need them partly because patients don't know to ask.

What "scaling" actually looks like

Three concrete paths the panel discussed:

1. Workforce expansion

Mid-career retraining is becoming more common. Nurse practitioners and PAs increasingly deliver these treatments alongside MDs. Continuing-medical-education programs in interventional psychiatry are growing.

Timeline: 3-7 years to materially shift workforce capacity.

2. Reimbursement reform

Pieces are moving. Insurance plans are slowly adding ketamine coverage. CMS (Medicare) coverage decisions have downstream effects on commercial plans. State-level psychedelic legalization (Oregon, Colorado) is creating new payment models.

Timeline: 5-10 years to reach broad insurance coverage parity.

3. Delivery innovation

This is the fastest piece. Telehealth has already shown that high-quality care can be delivered at home. The technology and clinical protocols exist now; the constraint is regulatory acceptance and physician comfort.

Timeline: already happening. Telehealth-supervised at-home protocols are accessible to most patients today.

What this means for you as a patient

If you're trying to access an interventional treatment for depression that hasn't responded to first-line care, here's the honest landscape in 2026:

• TMS is your most accessible in-network option if you live near a metro area. Insurance coverage is good. Effect builds over 6 weeks.
• Spravato is in-network through certified clinics if you have a documented treatment-resistant depression diagnosis. The 2-hour in-clinic monitoring per session is a significant workflow tax but coverage is solid.
• IV ketamine clinics are cash-pay almost everywhere. Effective but expensive ($400-800/session) and time-intensive.
• At-home ketamine therapy (telehealth-supervised oral or sublingual) is the most accessible option in terms of geography, time, and cost. Insurance coverage is rare but HSA/FSA accepted; pricing typically lower than IV clinics.
• VNS or ECT if you've moved through these and need more intensive options.

The most useful first conversation is with a physician who can review your specific situation. At Isha Health, initial consultations are 60-minute video visits, with no commitment to treatment.

The bigger picture

What was striking about the APA 2026 panel wasn't any single piece of advice. It was the shift in tone.

Five years ago, the conversation about interventional psychiatry was defensive — researchers and clinicians arguing that the evidence was real and these weren't fringe treatments. Now the evidence is settled. The conversation has moved to logistics: training, payment, delivery, awareness.

This is the boring middle of medical progress. Treatments that have proven they work, slowly making their way through insurance committees and clinical practice guidelines and patient awareness, until eventually they're just part of how psychiatry is done.

We're somewhere in the middle of that arc with ketamine. Probably 5-10 years from "standard treatment" — but only if patients keep asking, and only if delivery models keep expanding.

References

• McIntyre RS, Rosenblat JD. World Psychiatry 2021 — Definition and clinical staging of treatment-resistant depression
• Kelly TF et al. Brain Stimulation 2021 — Real-world outcomes of TMS for depression
• Wilkinson ST et al. JAMA Network Open 2023 — Patient-reported outcomes from real-world ketamine therapy
• FDA — Spravato (esketamine) approval announcement, March 2019
• FDA — TMS for depression — approval history and devices
• Berman RM et al. Biological Psychiatry 2000 — Foundational ketamine antidepressant trial
• Zarate CA et al. Archives of General Psychiatry 2006 — Ketamine in treatment-resistant depression
• WHO Essential Medicines List — Ketamine on the WHO Model List
• McAllister-Williams RH et al. J Affect Disord 2020 — Difficult-to-Treat Depression framework

---

Related Articles

• APA 2026 Annual Meeting Recap
• Vagus Nerve Stimulation for Depression
• The 40-Year Antidepressant Plateau
• Spravato vs Ketamine Infusion: Cost & Effectiveness

---

Considering ketamine therapy? Isha Health offers physician-led at-home treatment with an 88.8% improvement rate. Check appointment availability.